Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: crysball who wrote (412)	1/10/1999 3:36:00 AM
From: sam_b	Read Replies (2) of 1386

Today,Pharmos is currently providing additional data and sporadic questions for clarification .There are companies that R&D have essentially approved the possibility of commencing negotiation with. I believe that a contract with a big partner will be SIGNED. (probably April?).The orders of magnitude of payments to be paid by the partner stated in the table of Earning Model: members.iol.co.il are definitely acceptable in similar cases. Pharmos will conduct negotiations with a professional team skilled in such processes. All in all everything looks positive.The only negative aspect is the share price,which is not completely in line with reality. There are many shares on the market ,but apparently the great mass is in the hands of long term investors aware of the potential increase. As soon as demand generating factors are available, the share price will quickly increase. During the present quarter (Q1) the demand for Alrex must increase significantly.Up to today,from the drug's launch onto the market (June 1998) we have been out of season. We shall receive the true indication of it's potential at that time. SAM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next